Morgan Stanley analyst Ricky Goldwasser maintained a Buy rating on CVS Health (CVS) today and set a price target of $70.00. The company’s shares closed last Monday at $59.32.
According to TipRanks.com, Goldwasser is a 2-star analyst with an average return of -1.4% and a 44.3% success rate. Goldwasser covers the Services sector, focusing on stocks such as Charles River Labs, AmerisourceBergen, and Molina Healthcare.
Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $83.64, implying a 47.4% upside from current levels. In a report issued on March 24, RBC Capital also maintained a Buy rating on the stock with a $81.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $77.03 and a one-year low of $51.72. Currently, CVS Health has an average volume of 10.09M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
Read More on CVS:
